

August 14, 2025

Consolidated Financial Results for the Fiscal Year Ended June 30, 2025 (Under Japanese GAAP)

Company name: Asahi Intecc Co., Ltd.
 Listing: Tokyo Stock Exchange and Nagoya Stock Exchange
 Securities code: 7747
 URL: <https://www.asahi-intecc.co.jp/>
 Representative: Kenji Miyata, President & CEO
 Inquiries: Mizuho Ito, Member of Board & CFO, General Manager of Administration
 Telephone: +81-561-48-5551
 Scheduled date of annual general meeting of shareholders: September 25, 2025
 Scheduled date of commencing dividend payments: September 26, 2025
 Scheduled date of filing annual securities report: September 24, 2025
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended June 30, 2025 (from July 1, 2024 to June 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit excluding goodwill amortization, etc.		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
June 30, 2025	120,025	11.6	31,689	31.1	30,079	35.9	29,563	34.6	12,737	(19.4)
June 30, 2024	107,547	19.4	24,168	21.2	22,135	22.8	21,968	24.6	15,808	20.6

Note: Comprehensive income For the fiscal year ended June 30, 2025: ¥9,375 million (-59.0%)
 For the fiscal year ended June 30, 2024: ¥22,873 million (40.5%)

	Basic earnings per share	Diluted earnings per share	Return on equity	Ordinary profit to total assets ratio	Operating profit to net sales ratio
Fiscal year ended	Yen	Yen	%	%	%
June 30, 2025	46.92	—	8.4	15.4	25.1
June 30, 2024	58.20	—	11.2	12.1	20.6

Reference: Equity in earnings (losses)
 of affiliates For the fiscal year ended June 30, 2025: ¥— million
 For the fiscal year ended June 30, 2024: ¥— million

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
June 30, 2025	193,187	151,354	77.9	558.31
June 30, 2024	191,614	151,961	78.9	556.71

Reference: Equity
 As of June 30, 2025: ¥150,558 million
 As of June 30, 2024: ¥151,217 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended June 30, 2025	Million yen 40,543	Million yen -13,434	Million yen -8,107	Million yen 53,200
June 30, 2024	34,708	-21,222	-13,878	35,658

2. Dividends

	Annual dividends per share					Total dividends (total)	Payout ratio (consolidated)	Dividends to net assets ratio (consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
Fiscal year ended June 30, 2024	Yen —	Yen 0.00	Yen —	Yen 20.37	Yen 20.37	Million yen 5,533	% 35.0	% 3.9
June 30, 2025	—	0.00	—	24.23	24.23	6,534	51.6	4.3
Fiscal year ending June 30, 2026 (Forecast)	—	0.00	—	30.91	30.91		35.0	

3. Consolidated financial results forecast for the fiscal year ending June 30, 2026 (July 1, 2025 to June 30, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	130,870	9.0	32,642	8.5	32,809	11.0	23,811	86.9	88.30

* Notes

(1) Significant changes in scope of consolidation during the period: None

Newly included: -

Excluded: -

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(3) Number of issued shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2025	271,633,600 shares
As of June 30, 2024	271,633,600 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2025	1,964,677 shares
As of June 30, 2024	7,955 shares

(iii) Average number of shares during the period (cumulative)

Fiscal year ended June 30, 2025	271,476,579 shares
Fiscal year ended June 30, 2024	271,625,658 shares

(Reference) Summary of Non-Consolidated Financial Results

1. Non-consolidated financial results for the fiscal year ended June 30, 2025 (from July 1, 2024 to June 30, 2025)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Fiscal year ended								
June 30, 2025	86,493	17.2	21,496	55.3	36,685	163.5	21,662	98.8
June 30, 2024	73,810	15.8	13,841	12.8	13,922	13.2	10,895	50.7

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Fiscal year ended		
June 30, 2025	79.79	—
June 30, 2024	40.11	—

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of				
June 30, 2025	155,316	108,840	70.1	403.61
June 30, 2024	139,090	97,838	70.3	360.20

Reference: Equity

As of June 30, 2025: ￥108,840 million

As of June 30, 2024: ￥97,838 million

- * Financial results reports are exempt from review by certified public accountants or an audit corporation.
- * Proper use of earnings forecasts, and other special matters

Financial results forecasts and other forward-looking statements provided in these materials are based on information available to the Company and certain other assumptions deemed reasonable as of the date of publication of this document, and do not represent any guarantee that the Company will achieve these results. Actual financial results and other aspects of business performance may differ significantly from these forecasts owing to various factors. Please refer to “1. Overview of operating results, etc. (4) Future outlook” on page 5 of the attached materials for conditions forming the basis for financial results forecasts, notes regarding the use of financial results forecasts, and other information.

Table of contents of the attached materials

1. Overview of operating results, etc.	2
(1) Overview of operating results for the fiscal year under review	2
(2) Overview of financial position for the fiscal year under review	4
(3) Overview of cash flows for the fiscal year under review	4
(4) Future outlook.....	5
(5) Basic policy on profit distribution and dividends for the fiscal year under review and next fiscal year	7
2. Basic policy on selection of accounting standards.....	7
3. Consolidated financial statements and major notes	8
(1) Consolidated balance sheet.....	8
(2) Consolidated statements of income and comprehensive income	10
(3) Consolidated statement of changes in equity	12
(4) Consolidated statement of cash flows.....	14
(5) Notes to consolidated financial statements	16
(Note on entity's ability to continue as going concern).....	16
(Significant accounting policies for preparation of consolidated financial statements).....	16
(Significant accounting estimates)	20
(Changes in accounting policies)	20
(Changes in presentation).....	21
(Consolidated statement of income).....	21
(Consolidated statement of changes in equity)	22
(Revenue recognition).....	23
(Segment Information, etc.)	26
(Per share information)	31
(Significant subsequent events).....	31

1. Overview of operating results, etc.

(1) Overview of operating results for the fiscal year under review

The Asahi Intecc Group (the Group) has formulated the following four basic policies in the medium-term management plan “ASAHI Going Beyond 1000” (5-year plan started in July 2021), with its quantitative targets of consolidated net sales of 110,000 million yen and operating profit margin of 23–25% for the fiscal year ending June 30, 2026.

- 1) Strategic development of the global market and expansion of affected areas and treatment areas
- 2) Creating new businesses in global niche markets
- 3) Develop R&D and production system optimized for global expansion
- 4) Establish management structure for sustainable growth

As a result of advancing its businesses in line with these strategies, the Group successfully achieved net sales and operating profit margin targets in the fiscal year ended June 30, 2025, one year ahead of the original plan.

Our new medium-term management plan is as stated in “Notice concerning Formulation of New Mid-Term Management Plan “Building the Future 2030”” disclosed today (August 14, 2025). The Group aims to enhance corporate value by promoting these growth strategies under the plan in a steady manner.

As a result of advancing its businesses in line with the aforementioned strategies, the Group’s performance for the fiscal year ended on June 30, 2025 was as follows.

Net sales amounted to 120,025 million yen (an increase of 11.6% year on year), driven mainly by the strong performance of the Medical Division both domestically and internationally, supported by continued market share expansion and other factors.

Gross profit totaled 81,235 million yen (an increase of 17.6% year on year), due to the increase in net sales and improvement in the gross profit margin resulting from increased productivity, despite external negative factors such as appreciation of the Thai baht.

Operating profit was 30,079 million yen (an increase of 35.9% year on year), despite an increase in selling, general and administrative expenses, such as an increase in sales-related expenses aimed at strengthening sales in the non-cardiovascular field in the U.S. and in new fields in Japan, as well as an increase in R&D expenses.

Ordinary profit was 29,563 million yen (an increase of 34.6% year on year), due to an increase in subsidy income despite an increase in foreign exchange losses.

Profit attributable to owners of parent was 12,737 million yen (a decrease of 19.4% year on year), mainly due to the recording of extraordinary losses.

Foreign exchange rates used for the fiscal year under review:

149.72 yen per U.S. dollar (149.39 yen for the same period of the previous fiscal year, up 0.2%)

162.83 yen per euro (161.48 yen for the same period of the previous fiscal year, up 0.8%)

20.73 yen per Chinese yuan (20.64 yen for the same period of the previous fiscal year, up 0.4%)

4.41 yen per Thai baht (4.17 yen for the same period of the previous fiscal year, up 5.8%)

The operating results for each segment are outlined below.

From the beginning of the fiscal year under review, the method for measuring profit or loss in reportable segments has been changed.

For details, please refer to “3. Consolidated financial statements and major notes (5) Notes to consolidated financial statements (Segment information, etc.) 2. Explanation of measurements of sales, profit (loss), asset, liability, and other items for each reportable segment (Change in measurements of profit (loss) for each reportable segment.”

For comparative segment information, the figures for the previous fiscal year have been restated to reflect the new measurement method for segment information.

<Medical Division>

In the Medical Division, net sales remained brisk, increasing mainly due to continued market share expansion across all regions.

In the domestic market, net sales increased thanks to steady performance in the cardiovascular field, along

with favorable evaluations and strong performance of peripheral vascular products (imported purchased products) and neurovascular products in the non-cardiovascular field.

In the overseas market, net sales increased in both the cardiovascular and non-cardiovascular fields. In the cardiovascular field, net sales progressed very favorably across all regions, primarily for PCI guide wires and penetration catheters. In the non-cardiovascular field, despite a decline in OEM transactions in the U.S., net sales increased mainly due to the strong performance of neurovascular products in the Chinese market and abdominal vascular products in the U.S. market.

As a result, net sales totaled 107,779 million yen (an increase of 12.7% year on year).

Segment profit amounted to 33,445 million yen (an increase of 36.9% year on year).

<Device Division>

In the Device Division, net sales increased due to an increase in medical components, despite a decline in industrial components.

As for medical components, net sales increased mainly due to increasing transactions in cardiovascular inspection catheter components for Asia.

As for industrial components, net sales decreased mainly due to a decrease in leisure-related transactions in the overseas market, while machinery-related and construction-related transactions in the domestic and overseas markets increased.

As a result, net sales totaled 12,245 million yen (an increase of 3.0% year on year).

Segment profit amounted to 4,624 million yen (a decrease of 12.5% year on year), due to a decrease in revenues from intersegment transactions, etc.

(2) Overview of financial position for the fiscal year under review

As of June 30, 2025, total assets amounted to 193,187 million yen, an increase of 1,573 million yen from the end of the previous fiscal year. This was mainly due to an increase of 18,542 million yen in cash and deposits, despite decreases of 3,000 million yen in securities, 3,512 million yen in work in process, and 6,800 million yen in goodwill.

As for liabilities, total liabilities amounted to 41,833 million yen, an increase of 2,180 million yen from the end of the previous fiscal year. This was mainly due to an increase of 2,106 million yen in income taxes payable.

As for net assets, total net assets amounted to 151,354 million yen, a decrease of 607 million yen from the end of the previous fiscal year. This was mainly due to 4,446 million yen spent to purchase treasury shares and a decrease of 2,826 million yen in foreign currency translation adjustment, despite an increase of 7,204 million yen in retained earnings.

(3) Overview of cash flows for the fiscal year under review

The balance of cash and cash equivalents (hereinafter, “net cash”) during the fiscal year under review was 53,200 million yen (an increase of 49.2% year on year).

The status of cash flow and their factors during the fiscal year under review are as follows.

(Cash flows from operating activities)

Net cash provided by operating activities was 40,543 million yen (an increase of 5,835 million yen year on year). This was mainly due to profit before income taxes of 18,655 million yen, depreciation of 9,190 million yen, decrease in trade receivables of 1,166 million yen, decrease in inventories of 3,540 million yen, increase in advances received of 1,679 million yen, and recordings of 1,068 million yen in loss on valuation of investment securities and 9,244 million yen in impairment losses, despite income taxes paid of 6,213 million yen.

(Cash flows from investing activities)

Net cash used in investing activities was 13,434 million yen (a decrease of 7,787 million yen year on year). This was mainly due to purchase of investment securities of 14,325 million yen and purchase of property, plant and equipment of 8,096 million yen, despite proceeds from redemption of securities of 3,000 million yen and proceeds from sale of investment securities of 8,041 million yen.

(Cash flows from financing activities)

Net cash used in financing activities was 8,107 million yen (a decrease of 5,770 million yen year on year). This was mainly due to a repayments of long-term borrowings of 5,182 million yen, dividends paid of 5,533 million yen, and purchase of treasury shares of 4,446 million yen, despite proceeds from long-term borrowings of 8,500 million yen.

(4) Future outlook

The new medium-term management plan with the fiscal year ending June 30, 2026 as its first year is as stated in “Notice concerning Formulation of New Mid-Term Management Plan “Building the Future 2030”” disclosed today (August 14, 2025). The Group intends to maintain and expand growth continuously in the fiscal year ending June 30, 2026 by promoting these growth strategies under the plan in a steady manner.

(Million yen)

	Fiscal year ended June 30, 2025 Results	Fiscal year ending June 30, 2026 Forecast	Increase (Decrease)	Increase (Decrease) (%)
Net sales	120,025	130,870	10,844	9.0
Gross profit	81,235	86,786	5,550	6.8
(Percentage)	67.7	66.3	-1.4	—
Operating profit	30,079	32,642	2,562	8.5
(Percentage)	25.1	24.9	-0.1	—
Profit attributable to owners of parent	12,737	23,811	11,073	86.9

In this business forecast, the foreign exchange rates for major currencies are assumed as follows.

(Yen)	U.S. dollar	Euro	Chinese yuan	Thai baht
Fiscal year ending June 30, 2026: assumption	143.00	165.00	20.00	4.60
Fiscal year ended June 30, 2025: actual rate	149.72	162.83	20.73	4.41

In the case of the same exchange rate as the previous period

(Million yen)

	Fiscal year ended June 30, 2025 Results	Fiscal year ending June 30, 2026 Forecast	Increase (Decrease)	Increase (Decrease) (%)
Net sales	120,025	133,631	13,606	11.3
Gross profit	81,235	89,785	8,549	10.5
(Percentage)	67.7	67.2	-0.5	—
Operating profit	30,079	35,173	5,093	16.9
(Percentage)	25.1	26.3	1.3	—

<Net sales>

(Medical Division)

In the Medical Division, net sales are expected to increase mainly due to strong growth in the overseas market despite the negative impact of foreign exchange, with a stronger yen compared to foreign exchange rates assumptions at planning.

<Our own brand>

In the domestic market, net sales are expected to increase mainly due to an increase in peripheral vascular products associated with strengthening sales of purchased products and other factors in the non-cardiovascular field.

In the overseas market, through continued efforts to expand market share and other measures, net sales are expected to increase in both the cardiovascular field and the non-cardiovascular field in all regions despite the impact of a stronger yen. In the overseas cardiovascular field, since the number of cases is increasing significantly, mainly in the Chinese market, we will continue to aim for steady sales increase,

as well as market share expansion. In the overseas non-cardiovascular field, net sales are expected to increase in peripheral vascular products, neurovascular products, and abdominal vascular products. We will work to expand sales of peripheral vascular products and neurovascular products mainly in the U.S. market, and abdominal vascular products mainly in the U.S. and Chinese markets.

<OEM>

Net sales will see a decreasing trend mainly in the overseas market due to trends among customers and other factors.

(Device Division)

In the Device Division, net sales of both medical components and industrial components are expected to increase despite the negative impact of foreign exchange with a stronger yen compared to foreign exchange rates assumptions at planning. As for medical components, net sales are expected to increase mainly due to increasing transactions for the U.S. market. As for industrial components, net sales are expected to increase mainly due to a favorable trend of leisure-related transactions in addition to making Nitta Mold Co., Ltd. a consolidated subsidiary (in July 2025).

<Gross profit>

Gross profit is expected to increase along with an increase in revenue. Gross profit margin is expected to decline due to the impact of U.S. tariffs despite an increase resulting from increased productivity. If excluding the impact of U.S. tariffs, gross profit margin would increase.

<Selling, general and administrative expenses>

As for selling, general and administrative expenses, we plan to continue active prior investments for maintaining and further expanding future growth.

As for R&D expenses, the R&D-to-sales ratio is expected to be 9.9%.

As we plan to increase expenses mainly for sales and marketing activities in the U.S., sales-related expenses are expected to increase.

In addition to the expenses listed above, we assume increases in personnel expenses for strengthening the management structure.

<Non-operating income/expenses and extraordinary income/losses>

We do not expect any transactions having significant impact on non-operating income or expenses and extraordinary income or losses.

(5) Basic policy on profit distribution and dividends for the fiscal year under review and next fiscal year
(Basic policy on profit distribution)

We conduct business operations on a global scale and always aim to enhance corporate value. We recognize that returning some of our profits from business activities to shareholders is one of our important issues and adopt the basic policy of stable and continual distribution of dividends in consideration of consolidated financial results and other factors from a long-term perspective.

As a basic policy, we distribute dividends of surplus once a year as the year-end dividend. The decision on dividends is made by the general meeting of shareholders. However, the Articles of Incorporation stipulates that by a resolution of the Board of Directors, interim dividends provided for in Article 454, Paragraph 5 of the Companies Act may be distributed to shareholders or registered pledgees of shares listed or recorded in the final shareholder register as of December 31 every year.

We calculate the amount of dividends based on a long-term perspective and in comprehensive consideration of consolidated financial results for the fiscal year under review, future outlooks, the level of internal reserves, etc., targeting a consolidated dividend payout ratio of 35.0%.

Internal reserves will be used for R&D and capital investment indispensable for future growth and thus, we will make efforts to increase business performance and strengthen the financial position.

(Profit distribution for the fiscal year under review and next fiscal year)

Based on the above policy, we decided to pay 24.23 yen as the annual dividend for the fiscal year under review (consolidated dividend payout ratio of 51.6%). We plan to propose this matter at the 49th Annual General Meeting of Shareholders to be held on September 25, 2025 and based on the resolution, the formal decision will be made and the payment will be executed.

In addition, based on the above policy, we plan to pay 30.91 yen as the annual dividend for the next fiscal year (consolidated dividend payout ratio of 35.0%).

Dividends of surplus whose record date falls in the fiscal year under review are as follows:

Resolution date	Total amount of dividends	Dividend per share
September 25, 2025 Resolution at Annual General Meeting of Shareholders	6,534 million yen	24.23 yen

(Note) As announced in the "Notice Concerning Recording of Extraordinary Losses and Revision of Full-Year Financial Results Forecast" dated May 15, 2025, profit attributable to owners of parent for the fiscal year ended June 30, 2025 decreased due to recording of extraordinary losses, but dividends of surplus are not changed from the initial forecast at 24.23 yen.

2. Basic policy on selection of accounting standards

The Group's policy is to prepare consolidated financial statements in accordance with Japanese GAAP for the time being, taking into consideration the comparability of consolidated financial statement from period to period and from company to company.

As for the application of International Financial Reporting Standards (IFRS), the Group's policy is to take appropriate measures in consideration of various domestic and international circumstances.

3. Consolidated financial statements and major notes

(1) Consolidated balance sheet

(Million yen)

	Previous consolidated fiscal year (June 30, 2024)	Current consolidated fiscal year (June 30, 2025)
Assets		
Current assets		
Cash and deposits	35,658	54,200
Notes and accounts receivable - trade	17,676	15,767
Electronically recorded monetary claims - operating	1,913	2,026
Securities	3,000	–
Merchandise and finished goods	9,282	9,408
Work in process	12,298	8,785
Raw materials and supplies	7,763	6,458
Other	7,609	7,004
Allowance for doubtful accounts	-505	-291
Total current assets	94,696	103,359
Non-current assets		
Property, plant and equipment		
Buildings and structures	46,109	49,407
Accumulated depreciation	-14,523	-16,884
Buildings and structures, net	31,585	32,523
Machinery, equipment and vehicles	36,239	36,847
Accumulated depreciation	-25,683	-28,008
Machinery, equipment and vehicles, net	10,555	8,838
Land	7,257	7,301
Construction in progress	4,207	3,758
Other	14,463	15,851
Accumulated depreciation	-7,940	-9,190
Other, net	6,523	6,661
Total property, plant and equipment	60,129	59,082
Intangible assets		
Goodwill	6,910	110
Other	10,048	5,485
Total intangible assets	16,959	5,595
Investments and other assets		
Investment securities	15,185	19,389
Shares of subsidiaries and associates	220	335
Deferred tax assets	989	1,779
Other	3,538	4,384
Allowance for doubtful accounts	-105	-739
Total investments and other assets	19,828	25,149
Total non-current assets	96,917	89,827
Total assets	191,614	193,187

(Million yen)

	Previous consolidated fiscal year (June 30, 2024)	Current consolidated fiscal year (June 30, 2025)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	2,289	2,655
Electronically recorded obligations - operating	625	424
Short-term borrowings	5,615	2,387
Accounts payable - other	4,038	1,805
Income taxes payable	2,683	4,789
Provision for bonuses	2,700	2,868
Other	11,542	12,924
Total current liabilities	29,494	27,856
Non-current liabilities		
Long-term borrowings	1,087	6,633
Deferred tax liabilities	4,643	1,929
Provision for retirement benefits for directors (and other officers)	19	19
Retirement benefit liability	2,851	2,943
Asset retirement obligations	17	197
Lease liabilities	1,502	2,078
Other	36	174
Total non-current liabilities	10,157	13,976
Total liabilities	39,652	41,833
Net assets		
Shareholders' equity		
Share capital	18,860	18,860
Capital surplus	21,779	21,779
Retained earnings	90,742	97,947
Treasury shares	-7	-4,453
Total shareholders' equity	131,375	134,134
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,689	2,008
Foreign currency translation adjustment	17,142	14,315
Remeasurements of defined benefit plans	9	99
Total accumulated other comprehensive income	19,841	16,424
Non-controlling interests	744	795
Total net assets	151,961	151,354
Total liabilities and net assets	191,614	193,187

(2) Consolidated statements of income and comprehensive income

Consolidated statement of income

	(Million yen)	
	Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)	Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)
Net sales	107,547	120,025
Cost of sales	38,494	38,789
Gross profit	69,053	81,235
Selling, general and administrative expenses		
Freight-out	2,748	2,949
Provision of allowance for doubtful accounts	169	58
Salaries, wages and bonuses	11,280	12,926
Remuneration for directors (and other officers)	767	694
Director's bonuses	246	—
Provision for bonuses	1,291	1,458
Retirement benefit expenses	479	441
Depreciation	2,943	3,002
Research and development expenses	11,662	12,248
Other	15,329	17,376
Total selling, general and administrative expenses	46,917	51,155
Operating profit	22,135	30,079
Non-operating income		
Interest income	102	115
Dividend income	91	128
Subsidy income	79	918
Other	242	239
Total non-operating income	515	1,401
Non-operating expenses		
Interest expenses	226	214
Foreign exchange losses	379	1,455
Other	77	247
Total non-operating expenses	683	1,918
Ordinary profit	21,968	29,563
Extraordinary income		
Gain on sale of investment securities	21	23
Reversal of allowance for doubtful accounts	—	100
Total extraordinary income	21	123
Extraordinary losses		
Impairment losses	—	* 9,244
Loss on valuation of investment securities	99	1,068
Loss on valuation of shares of subsidiaries and associates	—	210
Provision of allowance for doubtful accounts for subsidiaries and associates	—	477
Provision of allowance for doubtful accounts	100	—
Other	0	31
Total extraordinary losses	199	11,031
Profit before income taxes	21,789	18,655
Income taxes - current	5,630	9,147
Income taxes - deferred	263	-3,284
Total income taxes	5,893	5,863
Profit	15,895	12,792
Profit attributable to non-controlling interests	87	54
Profit attributable to owners of parent	15,808	12,737

Consolidated statement of comprehensive income

(Million yen)

	Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)	Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)
Profit	15,895	12,792
Other comprehensive income		
Valuation difference on available-for-sale securities	656	-680
Foreign currency translation adjustment	6,274	-2,826
Remeasurements of defined benefit plans, net of tax	45	90
Total other comprehensive income	6,977	-3,417
Comprehensive income	22,873	9,375
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	22,684	9,323
Comprehensive income attributable to non-controlling interests	188	51

(3) Consolidated statement of changes in equity

Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)

(Million yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	18,860	21,727	78,867	-7	119,448
Changes during period					
Dividends of surplus			-3,933		-3,933
Profit attributable to owners of parent			15,808		15,808
Purchase of treasury shares				-0	-0
Purchase of shares of consolidated subsidiaries		52			52
Net changes in items other than shareholders' equity					
Total changes during period	-	52	11,874	-0	11,927
Balance at end of period	18,860	21,779	90,742	-7	131,375

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of period	2,033	10,867	-36	12,864	1,987	134,300
Changes during period						
Dividends of surplus						-3,933
Profit attributable to owners of parent						15,808
Purchase of treasury shares						-0
Purchase of shares of consolidated subsidiaries						52
Net changes in items other than shareholders' equity	656	6,274	45	6,977	-1,243	5,733
Total changes during period	656	6,274	45	6,977	-1,243	17,660
Balance at end of period	2,689	17,142	9	19,841	744	151,961

Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)

(Million yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	18,860	21,779	90,742	-7	131,375
Changes during period					
Dividends of surplus			-5,533		-5,533
Profit attributable to owners of parent			12,737		12,737
Purchase of treasury shares				-4,446	-4,446
Purchase of shares of consolidated subsidiaries		-			-
Net changes in items other than shareholders' equity					
Total changes during period	-	-	7,204	-4,446	2,758
Balance at end of period	18,860	21,779	97,947	-4,453	134,134

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of period	2,689	17,142	9	19,841	744	151,961
Changes during period						
Dividends of surplus						-5,533
Profit attributable to owners of parent						12,737
Purchase of treasury shares						-4,446
Purchase of shares of consolidated subsidiaries						-
Net changes in items other than shareholders' equity	-680	-2,826	90	-3,417	51	-3,365
Total changes during period	-680	-2,826	90	-3,417	51	-607
Balance at end of period	2,008	14,315	99	16,424	795	151,354

(4) Consolidated statement of cash flows

	(Million yen)	
	Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)	Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)
Cash flows from operating activities		
Profit before income taxes	21,789	18,655
Depreciation	8,464	9,190
Impairment losses	—	9,244
Increase (decrease) in allowance for doubtful accounts	273	427
Increase (decrease) in provision for bonuses	837	216
Increase (decrease) in retirement benefit liability	261	418
Interest and dividend income	-193	-244
Interest expenses	226	214
Amortization of goodwill	1,255	955
Loss (gain) on valuation of investment securities	99	1,068
Decrease (increase) in trade receivables	-2,345	1,166
Decrease (increase) in inventories	4,456	3,540
Increase (decrease) in trade payables	-973	190
Increase (decrease) in accounts payable - other	563	-851
Increase (decrease) in advances received	4,346	1,679
Decrease (increase) in accounts receivable - other	-337	-110
Other, net	1,289	992
Subtotal	40,014	46,756
Interest and dividends received	185	249
Interest paid	-167	-248
Income taxes paid	-5,323	-6,213
Net cash provided by (used in) operating activities	34,708	40,543

	(Million yen)	
	Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)	Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)
Cash flows from investing activities		
Purchase of securities	-3,000	—
Proceeds from redemption of securities	2,000	3,000
Purchase of investment securities	-8,334	-14,325
Proceeds from sale of investment securities	61	8,041
Purchase of property, plant and equipment	-9,877	-8,096
Purchase of intangible assets	-667	-482
Other, net	-1,403	-1,571
Net cash provided by (used in) investing activities	-21,222	-13,434
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	-6,500	-1,000
Proceeds from long-term borrowings	1,500	8,500
Repayments of long-term borrowings	-3,202	-5,182
Dividends paid	-3,933	-5,533
Purchase of treasury shares	0	-4,446
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	-1,355	—
Repayments of lease liabilities	-385	-446
Net cash provided by (used in) financing activities	-13,878	-8,107
Effect of exchange rate change on cash and cash equivalents	1,164	-1,459
Net increase (decrease) in cash and cash equivalents	773	17,542
Cash and cash equivalents at beginning of period	34,884	35,658
Cash and cash equivalents at end of period	35,658	53,200

(5) Notes to consolidated financial statements
(Note on entity's ability to continue as going concern)
Not applicable.

(Significant accounting policies for preparation of consolidated financial statements)

1. Scope of consolidation

(1) Number of consolidated subsidiaries 18

(2) Names of major consolidated subsidiaries

ASAHI INTECC THAILAND CO., LTD.

Filmecc Co., Ltd.

ASAHI INTECC USA, INC.

ASAHI INTECC HANOI CO., LTD.

ASAHI INTECC J-Sales CO., LTD.

ASAHI INTECC SCIENTIFIC (Beijing) Co., Ltd.

TOYOFLEX CEBU CORPORATION

ASAHI INTECC EUROPE B.V.

Asahi Intecc Medical Device (Nanning) Co., Ltd., which was newly established, has been included in the scope of consolidation from the fiscal year under review.

(3) Names of non-consolidated subsidiaries

Nihon Chemical Coat Co., Ltd.

FICUS Co., Ltd.

walkey Inc.

LAKE R&D Inc.

Magnaire Co., Ltd.

Nitta Mold Co., Ltd.

NITTA M&T (THAILAND) CO., LTD.

Reason for exclusion from the scope of consolidation

The seven non-consolidated subsidiaries are small in size, and the total assets, net sales, profit or loss (the Company's share), retained earnings (the Company's share), etc. of these companies do not have a material impact on the consolidated financial statements.

2. Application of the equity method

Non-consolidated subsidiaries and affiliated companies not accounted for using the equity method

Nihon Chemical Coat Co., Ltd.

FICUS Co., Ltd.

walkey Inc.

LAKE R&D Inc.

Magnaire Co., Ltd.

Nitta Mold Co., Ltd.

NITTA M&T (THAILAND) CO., LTD.

ELDORET HOSPITAL-ASAHI INTECC HEART CENTRE

Reason for not applying the equity method

As for the eight non-consolidated subsidiaries and affiliated companies not accounted for using the equity method, the impact of excluding them from the scope of equity method on the consolidated financial statements is minimal given their profit or loss (the Company's share), retained earnings (the Company's

share), etc., and the impact is immaterial as a whole.

3. Fiscal years of consolidated subsidiaries

Out of the Company's consolidated subsidiaries, ASAHI INTECC SCIENTIFIC (Beijing) Co., Ltd., Asahi Intecc Medical Device (Nanning) Co., Ltd., and ASAHI INTECC CIS LLC end their fiscal years on December 31.

When preparing the consolidated financial statements, financial statements based on a provisional settlement of accounts conducted as of the consolidated fiscal year-end are used for these companies.

4. Accounting policies

(1) Basis and method of valuation of important assets

a) Securities

Securities to be held to maturity

Cost method

Available-for-sale securities

Securities other than shares that do not have a market value

Measured at fair value

(Valuation differences are reported as a component of net assets. The cost of securities sold is calculated using the moving-average method.)

Shares that do not have a market value

Measured at cost using the moving-average method

b) Inventories

Merchandise and finished goods, work in process, and raw materials

Measured at cost, primarily determined by the periodic average method

(The carrying amount in the balance sheet is calculated with consideration of write-downs due to decreased profitability.)

Supplies

Measured at cost, determined by the last purchase price method

(The carrying amount in the balance sheet is calculated with consideration of write-downs due to decreased profitability.)

(2) Method of depreciation and amortization of important depreciable and amortizable assets

a) Property, plant and equipment (excluding leased assets)

Depreciated mainly using the straight-line method.

The range of useful lives is as follows:

Buildings and structures	10 to 47 years
--------------------------	----------------

Machinery, equipment and vehicles	5 to 10 years
-----------------------------------	---------------

b) Intangible assets

Amortized using the straight-line method.

The Company and its consolidated subsidiaries in Japan amortize software for internal use over the expected useful life within respective companies (five years).

c) Leased assets

Amortized using the straight-line method based on the assumption that the useful lives are equivalent to the lease terms and the residual value is zero.

Leased assets are presented as part of "other" under "property, plant and equipment."

(3) Basis for recording important provisions

a) Allowance for doubtful accounts

At the Company and its consolidated subsidiaries in Japan, allowance for doubtful accounts is provided for possible losses arising from bad debts at an amount determined based on the historical default rates for general receivables, and an individual estimate of uncollectible amounts for specific doubtful receivables from customers experiencing financial difficulties.

At overseas consolidated subsidiaries, allowance for doubtful accounts is provided at an amount determined based on an individual estimate of uncollectible amounts.

b) Provision for bonuses

Provision for bonuses is recorded at an estimated amount attributable to the fiscal year under review to provide for future bonus payments to employees.

c) Provision for retirement benefits for directors (and other officers)

The Company abolished the officer retirement benefit system in September 2005. The balance of provision for retirement benefits for directors (and other officers) as of the end of the fiscal year under review is the estimated amount to be paid to officers who were in office when the system was abolished. The payments will be made when each officer retires.

(4) Basis for accounting treatments on retirement benefit

Retirement benefit liability is recorded at an estimated amount of retirement benefit obligations and pension assets as of the end of the fiscal year under review to provide for future retirement benefits to employees.

(i) Method for attributing estimated retirement benefits to individual periods of service

In calculating the retirement benefit obligations, the benefit formula basis is adopted for the purpose of attributing estimated retirement benefits to the period up to the end of the fiscal year under review.

(ii) Calculation of actuarial gain or loss and prior service cost

Actuarial gain or loss is amortized from the following fiscal year on a straight-line basis over a certain period shorter than the average remaining years of service of the eligible employees at the time of the gain or loss arising during each fiscal year (primarily five years).

Prior service cost is amortized on a straight-line basis over a certain period (12 years), which is within the average remaining years of service period of the eligible employees at the time the cost arising.

(iii) Adoption of short-cut method at small companies, etc.

Certain consolidated subsidiaries apply the short-cut method when calculating retirement benefit liability and retirement benefit expenses, under which the amount of retirement benefit that must be paid if employees retire for personal reasons at the end of the fiscal year is deemed to be the amount of retirement benefit obligations.

(5) Significant revenue and expense recognition standards

The details of main performance obligations in main businesses related to revenue arising from contracts with customers of the Company and its consolidated subsidiaries and the usual timing of fulfillment of the performance obligation (the usual timing of revenue recognition) are as follows.

The Medical Division mainly engages in sales of medical products and the Device Division mainly engages in sales of industrial products. Regarding sales of these products, revenue is mainly recognized when goods and products are each delivered to a customer, because at such time, legal ownership, physical possession, material risk associated with ownership, and economic value of those goods and products are transferred to the customer and the right to receive payment is finalized.

The consideration under sales contracts of the Group's products is generally received within one to three months after delivery of products to a customer based on contracts with customers and does not include significant financial elements.

(6) Translation of significant assets and liabilities denominated in foreign currencies into Japanese yen

Receivables and payables denominated in foreign currencies are translated into Japanese yen at the exchange rate prevailing at the end of the consolidated fiscal year and resulting exchange gains and losses are included in net profit or loss. Assets and liabilities of overseas consolidated subsidiaries are translated into yen at the exchange rate prevailing on the respective fiscal year-ends of those subsidiaries. Income and expenses are translated at the average rate of market price during the fiscal year and resulting translation adjustments are included in net assets as foreign currency translation adjustment under accumulated other comprehensive income.

(7) Amortization method and period of goodwill

Goodwill is amortized using the straight-line method over five to twenty years.

(8) Scope of funds in the consolidated statement of cash flows

These funds include cash on hand, deposits that can be withdrawn on demand, and short-term investments that can be easily converted into cash and bear only minor risks with respect to fluctuation of value with their redemption deadline arriving within three months from the acquisition date.

(Significant accounting estimates)

(Impairment of goodwill and other intangible assets)

1. Amounts recorded in the consolidated financial statements for the current consolidated fiscal year

	Previous consolidated fiscal year	Current consolidated fiscal year
Goodwill	6,910 million yen	110 million yen
Other intangible assets	7,962 million yen	3,814 million yen
Impairment losses on goodwill and other intangible assets	–	9,244 million yen

2. Information on details of significant accounting estimates related to identified items

The Group considers goodwill as excess earnings power expected from future business development of the acquired companies and synergistic effects within the Group. The business plans used for calculating share value, which is a basis for evaluation of goodwill, includes significant assumptions such as future sales estimates and schedules until products under development are released. Evaluation of intangible assets includes significant assumptions such as the aforementioned business plans as well as customer attrition rates related to customer-related assets. After confirming future sales estimates and the state of progress toward product releases based on said assumptions, the Group identifies the existence of any signs of impairment on goodwill and other intangible assets. If any sign of impairment is determined to exist, the Group determines the necessity of recognition of impairment loss.

Considering the latest business environment and future business plans, it was determined that the investments in ASAHI SURGICAL ROBOTICS CO., LTD., Pathways Medical Corporation, Rev.1 Engineering, Inc., and Asahi Medical Technologies, Inc. were no longer recoverable mainly due to a decline in profitability. Accordingly, impairment losses were recorded on goodwill and other intangible assets, etc. in the fiscal year under review.

The recoverable amount was calculated based on value in use. However, following a review of future plans, the cash outflows required to maintain and operate the assets over the estimation period were determined to exceed the cash inflows generated by their use, and accordingly, the value in use was calculated as zero.

Assumptions used for said accounting estimates and determination are based on information available at the end of the fiscal year under review. Occurrence of any event that requires revision to assumptions such as future business plans, future sales forecasts, and customer attrition rates may significantly affect evaluation of goodwill and other intangible assets in the consolidated financial statements for the next fiscal year.

(Changes in accounting policies)

(Application of accounting standard for current income taxes, etc.)

The Company has applied the “Accounting Standard for Current Income Taxes” (ASBJ Statement No. 27, October 28, 2022; the “2022 Revised Accounting Standard”), etc. from the beginning of the fiscal year under review.

For the revisions to the accounting classification of current income taxes (taxation on other comprehensive income), the Company follows the transitional treatment specified in the proviso to Paragraph 20-3 of the 2022 Revised Accounting Standard and the transitional treatment specified in the proviso to Paragraph 65-2 (2) of the “Guidance on Accounting Standard for Tax Effect Accounting” (ASBJ Guidance No. 28, October 28, 2022; the “2022 Revised Guidance”).

This application has no impact on the consolidated financial statements.

For the revisions related to the review of treatment in consolidated financial statements when conducting a tax deferral of gains or losses on sales arising from the sale of subsidiary shares, etc. between consolidated companies, the Company has applied the 2022 Revised Guidance from the beginning of the fiscal year under review.

This application has no impact on the consolidated financial statements for the previous fiscal year.

(Changes in presentation)

(Consolidated balance sheet)

“Lease liabilities,” which was included in “other” under “non-current liabilities” for the previous fiscal year, is presented separately from the current fiscal year due to an increase in financial materiality. To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, in the consolidated balance sheet for the previous fiscal year, 1,539 million yen presented as “other” under “non-current liabilities” has been reclassified as 1,502 million yen presented as “lease liabilities” and 36 million yen presented as “other.”

(Consolidated statement of cash flows)

“Proceeds from sale of investment securities,” which was included in “other, net” under “cash flows from investing activities” for the previous fiscal year, and “purchase of treasury shares,” which was included in “other, net” under “cash flows from financing activities” for the previous fiscal year, are presented separately from the current fiscal year due to an increase in materiality. To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, in the consolidated statement of cash flows for the previous fiscal year, -1,342 million yen presented as “other, net” under “cash flows from investing activities” has been reclassified as 61 million yen presented as “proceeds from sale of investment securities” and -1,403 million yen presented as “other, net,” and 0 million yen presented as “other, net” under “cash flows from financing activities” has been reclassified as 0 million yen presented as “purchase of treasury shares.”

(Consolidated statement of income)

*Impairment losses

During the fiscal year under review, the Company recorded impairment losses related to the following asset groups.

Subsidiary (Location)	Use	Type	Impairment loss (Million yen)
ASAHI SURGICAL ROBOTICS CO., LTD. (Kashiwa, Chiba)	Business assets	Goodwill and other intangible assets, etc.	1,992
Pathways Medical Corporation (California, USA)	Business assets	Goodwill and other intangible assets, etc.	3,636
Rev.1 Engineering, Inc. (California, USA)	Business assets	Goodwill and other intangible assets, etc.	1,623
ASAHI Medical Technologies, Inc. (California, USA)	Business assets	Goodwill, etc.	1,991

The Group defines asset groups based on managerial accounting units, grouping them by the smallest units that generate independent cash flows.

Considering the business environment and future business plans, it was determined that the investments in the above consolidated subsidiaries were no longer recoverable mainly due to a decline in profitability.

Accordingly, impairment losses were recorded on goodwill and other intangible assets, etc.

The recoverable amount was calculated based on value in use. However, following a review of future plans, the cash outflows required to maintain and operate the assets over the estimation period were determined to exceed the cash inflows generated by their use, and accordingly, the value in use was calculated as zero.

(Consolidated statement of changes in equity)

Previous consolidated fiscal year (From July 1, 2023 to June 30, 2024)

1. Matters concerning the class and total number of issued shares and the class and number of treasury shares

Class of shares	Number of shares at the beginning of the fiscal year under review (shares)	Increase (shares)	Decrease (shares)	Number of shares at the end of the fiscal year under review (shares)
Issued shares				
Common shares	271,633,600	–	–	271,633,600
Treasury shares				
Common shares	7,912	43	–	7,955

(Summary of the changes)

Treasury shares

Increase due to purchase of shares less than one unit: 43 shares

Current consolidated fiscal year (From July 1, 2024 to June 30, 2025)

1. Matters concerning the class and total number of issued shares and the class and number of treasury shares

Class of shares	Number of shares at the beginning of the fiscal year under review (shares)	Increase (shares)	Decrease (shares)	Number of shares at the end of the fiscal year under review (shares)
Issued shares				
Common shares	271,633,600	–	–	271,633,600
Treasury shares				
Common shares	7,955	1,956,722	–	1,964,677

(Summary of the changes)

Treasury shares

Increase due to purchase of shares less than one unit: 22 shares

Increase due to market purchase for acquisition of treasury shares: 1,956,700 shares

(Revenue recognition)

(1) Disaggregation of revenue from contracts with customers

(1) Breakdown by type

Previous consolidated fiscal year (From July 1, 2023 to June 30, 2024)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	72,690	—	72,690
Non-cardiovascular	15,346	—	15,346
OEM	7,618	—	7,618
Medical Components	—	7,525	7,525
Industrial Components	—	4,367	4,367
Total	95,654	11,892	107,547

Current consolidated fiscal year (From July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	81,202	—	81,202
Non-cardiovascular	18,983	—	18,983
OEM	7,593	—	7,593
Medical Components	—	8,019	8,019
Industrial Components	—	4,226	4,226
Total	107,779	12,245	120,025

(2) Breakdown by region

Previous consolidated fiscal year (From July 1, 2023 to June 30, 2024)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	14,727	2,732	17,460
North America	21,066	4,210	25,276
Europe	22,121	418	22,539
China	24,033	582	24,616
Others	13,705	3,948	17,654
Total	95,654	11,892	107,547

Current consolidated fiscal year (From July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	16,074	2,805	18,880
North America	23,043	3,975	27,018
Europe	24,148	496	24,645
China	28,283	539	28,823
Others	16,229	4,428	20,658
Total	107,779	12,245	120,025

(2) Disaggregation of revenue from contracts with customers

Useful information in understanding revenue is as presented in “(Significant accounting policies for preparation of consolidated financial statements), 4. Accounting policies, (5) Significant revenue and expense recognition standards.”

(3) Information on relationship of fulfillment of performance obligations based on contracts with customers with cash flow generated from said contracts and the amount and period of revenue expected to be recognized in the next and subsequent fiscal years from contracts with customers' existing at the end of the fiscal year under review

Previous consolidated fiscal year (From July 1, 2023 to June 30, 2024)

1. Balance of contract liabilities, etc.

(Million yen)

	Fiscal year under review
Contract liabilities (beginning balance)	3,255
Contract liabilities (ending balance)	8,182

Contract liabilities are mainly related to advances received from customers. Contract liabilities are reversed upon recognition of revenue.

Revenue recognized in the fiscal year under review that was included in the contract liability balance at the beginning of the fiscal year under review was 3,255 million yen. The increase of 4,927 million yen in contract liabilities in the fiscal year under review was mainly attributable to an increase in advances received.

2. Transaction price allocated to the remaining performance obligations

The Group has applied a practical expedient and does not provide information on the remaining performance obligations as the Group has no significant transaction of which the original expected period is one year or more. Consideration promised in contracts with customers does not have any significant amounts not included in the transaction price.

Current consolidated fiscal year (From July 1, 2024 to June 30, 2025)

1. Balance of contract liabilities, etc.

(Million yen)

	Fiscal year under review
Contract liabilities (beginning balance)	8,182
Contract liabilities (ending balance)	9,184

Contract liabilities are mainly related to advances received from customers. Contract liabilities are reversed upon recognition of revenue.

Revenue recognized in the current fiscal year that was included in the contract liability balance at the beginning of the current fiscal year was 8,182 million yen. The increase of 1,001 million yen in contract liabilities in the current fiscal year was mainly attributable to an increase in advances received.

2. Transaction price allocated to the remaining performance obligations

The Group has applied a practical expedient and does not provide information on the remaining performance obligations as the Group has no significant transaction of which the original expected period is one year or more. Consideration promised in contracts with customers does not have any significant amounts not included in the transaction price.

(Segment Information, etc.)

[Segment Information]

1. Description of reportable segments

The Company's reportable segments are components of the Company for which separate financial information is available and subject to periodical reviews by the Board of Directors to determine allocation of management resources and evaluate business performance.

The Group has established operating divisions by business area to conduct integrated business activities from development to manufacturing and sales. Based on these operating divisions, the Medical Division and the Device Division have been established as two reportable segments.

The Medical Division engages in development, manufacturing and sales of our own brand products and OEM products in the medical device field and the Device Division engages in development, manufacturing and sales of components and other products in the medical device and industrial device fields.

2. Explanation of measurements of sales, profit (loss), asset, liability, and other items for each reportable segment

The accounting method for the reported business segments is generally the same as the method stated in "significant accounting policies for preparation of consolidated financial statements."

Profit of reportable segments is based on operating profit.

Transactions with other segments are mainly based on market prices and manufacturing costs.

(Change in measurements of profit (loss) for each reportable segment)

From the beginning of the fiscal year under review, general and administrative expenses for certain consolidated subsidiaries, which were previously included in the Medical Division and Device Division segments, have been reclassified as general and administrative expenses that do not belong to any reportable segment (corporate expenses) due to organizational expansion.

Segment information for the previous consolidated fiscal year has been prepared and disclosed based on the revised measurement method.

3. Disclosure of sales, profit (loss), asset, liability, and other items for each reportable segment

Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	95,654	11,892	107,547	–	107,547
Transactions with other segments	–	14,257	14,257	-14,257	–
Total	95,654	26,150	121,804	-14,257	107,547
Segment profit	24,426	5,287	29,713	-7,577	22,135
Segment assets	117,068	46,010	163,078	28,535	191,614
Other items					
Depreciation	4,697	3,285	7,983	481	8,464
Increase in property, plant and equipment and intangible assets	6,065	5,600	11,665	904	12,570

Notes: 1. Adjustments are as follows:

- (i) The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
- (ii) The adjustment to segment assets includes intersegment elimination of 565 million yen and corporate assets that are not allocated to each reportable segment of 27,969 million yen.
- (iii) The adjustment to increase in property, plant and equipment and intangible assets includes an increase of corporate assets that do not belong to any reportable segment such as payment relating to the construction of welfare facilities.

- 2. Segment profit is adjusted with the operating profit in the consolidated statement of income.
- 3. Basis of allocation for non-current assets to each segment is different from that for related depreciation.

Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	107,779	12,245	120,025	–	120,025
Transactions with other segments	–	14,151	14,151	-14,151	–
Total	107,779	26,396	134,176	-14,151	120,025
Segment profit	33,445	4,624	38,069	-7,990	30,079
Segment assets	113,132	49,647	162,779	30,407	193,187
Other items					
Depreciation	5,190	3,427	8,617	572	9,190
Increase in property, plant and equipment and intangible assets	2,927	4,232	7,159	1,288	8,447

Notes: 1. Adjustments are as follows:

- (i) The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
- (ii) The adjustment to segment assets includes intersegment elimination of 259million yen and corporate assets that are not allocated to each reportable segment of 30,148million yen.
- (iii) The adjustment to increase in property, plant and equipment and intangible assets includes an increase of corporate assets that do not belong to any reportable segment such as payment relating to the construction of welfare facilities.

2. Segment profit is adjusted with the operating profit in the consolidated statement of income.

3. Basis of allocation for non-current assets to each segment is different from that for related depreciation.

[Information associated with reportable segments]

Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)

1. Information for each product or service

This is omitted as the same information is disclosed in the segment information section.

2. Information for each region

(1) Net sales

(Million yen)

Japan	U.S.	Europe	China	Others	Total
17,460	24,746	22,539	24,616	18,184	107,547

Note: Net sales are classified by countries or regions based on the location of customers.

(2) Property, plant and equipment

(Million yen)

Japan	Thailand	Vietnam	Philippines	Others	Total
27,238	14,713	7,555	9,090	1,530	60,129

3. Information for each of main customers

Not applicable.

Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)

1. Information for each product or service

This is omitted as the same information is disclosed in the segment information section.

2. Information for each region

(1) Net sales

(Million yen)

Japan	U.S.	Europe	China	Others	Total
18,880	26,381	24,645	28,823	21,295	120,025

Note: Net sales are classified by countries or regions based on the location of customers.

(2) Property, plant and equipment

(Million yen)

Japan	Thailand	Vietnam	Philippines	Others	Total
28,589	13,446	7,422	8,622	1,001	59,082

3. Information for each of main customers

Not applicable.

[Disclosure of impairment losses on non-current assets for each reportable segment]

Previous consolidated fiscal year (From July 1, 2023 to June 30, 2024)

Not applicable.

Current consolidated fiscal year under review (From July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment			Unallocated amounts and elimination	Total
	Medical Division	Device Division	Subtotal		
Impairment losses	9,244	–	9,244	–	9,244

[Amortization and unamortized balance of goodwill for each reportable segment]

Previous consolidated fiscal year (From July 1, 2023 to June 30, 2024)

(Million yen)

	Reportable segment			Unallocated amounts and elimination	Total
	Medical Division	Device Division	Subtotal		
Amortization during the period	1,255	–	1,255	–	1,255
Balance at end of the period	6,910	–	6,910	–	6,910

Current consolidated fiscal year under review (From July 1, 2024 to June 30, 2025)

(Million yen)

	Reportable segment			Unallocated amounts and elimination	Total
	Medical Division	Device Division	Subtotal		
Amortization during the period	955	–	955	–	955
Balance at end of the period	110	–	110	–	110

[Information about gain on bargain purchase for each reportable segment]

Not applicable.

(Per share information)

	Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)	Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)
Net assets per share	556.71 yen	558.31 yen
Basic earnings per share	58.20 yen	46.92 yen

Note: The basis for calculating basic earnings per share is as follows.

Items	Previous consolidated fiscal year (from July 1, 2023 to June 30, 2024)	Current consolidated fiscal year (from July 1, 2024 to June 30, 2025)
Basic earnings per share		
Profit attributable to owners of parent (million yen)	15,808	12,737
Amount not attributable to common shareholders (million yen)	—	—
Profit attributable to owners of parent regarding common stock (million yen)	15,808	12,737
Average number of common stock during the period (thousand shares)	271,625	271,476

(Significant subsequent events)

Not applicable.